The estimated Net Worth of Kristen Harrington Smith is at least $781 Thousand dollars as of 15 November 2022. Ms Smith owns over 25,000 units of Immunogen stock worth over $781,000 and over the last 3 years she sold IMGN stock worth over $0.
Ms has made over 1 trades of the Immunogen stock since 2022, according to the Form 4 filled with the SEC. Most recently she exercised 25,000 units of IMGN stock worth $781,000 on 15 November 2022.
The largest trade she's ever made was exercising 25,000 units of Immunogen stock on 15 November 2022 worth over $781,000. On average, Ms trades about 12,500 units every 0 days since 2021. As of 15 November 2022 she still owns at least 25,000 units of Immunogen stock.
You can see the complete history of Ms Smith stock trades at the bottom of the page.
Kristen Harrington-Smith is the Sr. VP & Chief Commercial Officer at Immunogen.
Kristen's mailing address filed with the SEC is C/O IMMUNOGEN, INC., 830 WINTER STREET, WALTHAM, MA, 02451.
Over the last 21 years, insiders at Immunogen have traded over $72,947,831 worth of Immunogen stock and bought 303,125 units worth $974,603 . The most active insiders traders include Biochem Incshire Pharmaceut..., Capital, L.P.Morton Holding..., and Mark J Enyedy. On average, Immunogen executives and independent directors trade stock every 34 days with the average trade being worth of $2,554,057. The most recent stock trade was executed by Stacy Ann Coen on 2 February 2024, trading 14,350 units of IMGN stock currently worth $448,294.
immunogen is a clinical-stage biotechnology company that develops targeted anticancer therapeutics with its proprietary antibody-drug conjugate (adc) technology. the company's lead product candidate, mirvetuximab soravtansine, is a potential treatment for folate receptor α-positive ovarian cancers and other solid tumors. leading healthcare companies have licensed rights to use immunogen's technology to develop novel anticancer therapies, and roche's marketed product, kadcyla, utilizes immunogen's adc technology. more information about the company can be found at www.immunogen.com.
Immunogen executives and other stock owners filed with the SEC include: